PSS11 Economic Evaluation of Biologic Treatments for Moderate to Severe Psoriasis in Italy  by Marcellusi, A. et al.
2012. Supplementary material was identified by a manual examination of litera-
ture. Studies published between 1998 and 2011 were selected using predefined
criteria. Quality of the articles was rated by two independent investigators. Avail-
able data related to resource utilization and costs were extracted and cost units
calculated for Germany. RESULTS: A total of 66 articles were identified. After the
first abstract screening 24 full-text articles were identified as relevant. Finally, after
full-text screening, 10 articles could be included. The majority of studies focused on
the societal economic burden of both impairments. Indirect costs were highest
amongst all cost categories due to productivity loss. Only two identified articles
reported data for Germany. Out of these, one European study transferred survey
data from abroad to the German system and another article reported costs for
specific ophthalmological diseases. CONCLUSIONS: There is a dearth of literature
assessing the economic impact of visual impairment and blindness in Germany
indicating a need for research to fill this gap. Therefore, in a second step, we will
conduct a cost-of-illness study using a bottom-up approach to explore cost units in
detail, as well as their determinants and intangible effects for Germany.
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OBJECTIVES: Psoriasis is a chronic disease that impacts significantly on patients’
quality of life (QoL). Biological drugs interfere in the immunologic process that
triggers and supports psoriasis and, therefore, prove effective in its treatment. The
aim of this study was to perform a cost-utility analysis (CUA) comparing biologic
treatments (adalimumab, etanercept, infliximab, and ustekinumab) in Italy.
METHODS: A decision tree model previously applied to the UK was adapted for
Italy using resource and cost data from the Italian Ministry of Health (Ministero
della Salute). Clinical efficacy in the treatment of moderate to severe psoriasis was
determined by the Psoriasis Area Criteria and Severity Index (PASI). Relative effi-
cacy of biologic treatments was based on a network meta-analysis of clinical trials.
A different level of utility is associated with each level of PASI response. Costs
included hospitalization, drug acquisition, administration, and monitoring over a
10-year time horizon. Incremental cost-effectiveness ratios (ICERs) compared with
supportive care (no systemic therapy) were expressed as euros/quality-adjusted
life year (QALY). One-way sensitivity analyses, where key parameters were
changed to alternative plausible values, explored uncertainty in the results.
RESULTS: In the base case, adalimumab was found to be the most cost effective
compared to supportive care (ICER: €52,583), followed by ustekinumab 90 mg (ICER:
€52,846), ustekinumab 45 mg (ICER: €54,997), infliximab (ICER: €56,141), etanercept
50 mg BIW (ICER: €77,611), and etanercept 25 mg BIW (ICER: €78,194). The ICER for
ustekinumab 90 mg, ustekinumab 45mg, and infliximab compared to adalimumab
were €57,052, €140,445, and €86,794, respectively. Adalimumab remained the most
cost-effective over the vast majority of the one-way sensitivity analyses.
CONCLUSIONS: The analysis demonstrated that adalimumab is the most cost-
effective biologic for the treatment of patients affected by moderate to severe
psoriasis.
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OBJECTIVES: Treatment strategies for the prevention of macular oedema (MO) in
diabetic patients include the postoperative use of steroids with and without anti-
biotics. However, measured with optimal coherence tomography (OCT), between
14% and 22% of diabetic patients still experience postoperative MO, with 3.05%
developing clinically significant MO (CSMO). Nepafenac has recently been granted
approval in Scotland for the licensed indication of reduction in risk of postopera-
tive MO associated with cataract surgery in diabetic patients. The primary objective
was to therefore estimate the incremental cost-effectiveness ratio (ICER) of
Nepafenac compared to the identified standard practice of Prednisolone Acetate
Ophthalmic Suspension (PAOS). METHODS: An Excel-based cost-utility model was
developed with a 90-day time horizon (base-case). An appropriate comparator was
established via consultation with an expert advisory-board comprised of 3 oph-
thalmologists currently practising in Scotland. Effectiveness data were derived
from the pivotal study, C-07-43, whereby the primary outcome demonstrated that
a significantly smaller percentage of patients in the Nepafenac group developed
MO relative to patients in the vehicle group (3.2% vs 16.7%; p0.001). The difference
at 90 days was converted to a RR of MO  0.19. Costs comprised drug acquisition
and outpatient costs, the latter including physician visits and OCT, derived from
ISD Scotland and the BNF 63. Importantly, costs were only associated with those
patients with clinically diagnosed MO. In terms of utilities, an algorithm associat-
ing logMAR visual acuity (VA) with health-related utility estimated with TTO was
used to populate the model. RESULTS: Nepafenac had an ICER of £6,552 per QALY
compared to PAOS in the base-case scenario. CONCLUSIONS: Nepafenac is highly
cost-effective compared to Prednisolone Acetate, and with a concomitant low bud-
get impact (estimated annual maximum of £110,500), should be considered as the
primary treatment for reduction in risk of postoperative MO associated with cata-
ract surgery in diabetic patients.
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OBJECTIVES: Up to 21% of adults will develop tinnitus, manifesting the perception
of a noxious disabling internal sound. Many different treatments are offered, but
evidence on their effectiveness and cost-effectiveness is scarce or absent. Recently,
the effectiveness of a specialised treatment of tinnitus based on cognitive behav-
ioural therapy was demonstrated (Cima et al., 2012). The present study evaluates
the cost-effectiveness of this treatment compared to care as usual, in an audiolog-
ical centre. METHODS: An economic evaluation was carried out alongside a ran-
domized controlled clinical trial. The economic evaluation was conducted from a
societal perspective, using a one-year time horizon. The incremental cost effective-
ness ratio (iCER) was calculated by dividing the difference in costs by the difference
in Quality Adjusted Life Years (QALYs) based on the HUI Mark III. Non-parametric
bootstrapping and sensitivity analyses were used to asses the uncertainty in costs
and effects. Sensitivity analysis included a complete cases analysis and analysis on
data were missing values on the HUI mark III were imputed based on a mixed
regression model from the clinical effectiveness analysis. RESULTS: Compared to
patients receiving usual care, patients who received specialised care gained on
average 0.015 QALYs (BCI:-0.028-0.055) The incremental costs from a societal per-
spective are €286 (BCI:-€828-€1427). The incremental cost per QALY from a societal
perspective amounted to €19,688. The probability that SC is cost-effective from a
societal perspective is 57% for a willingness to pay for a QALY of €35,000.
CONCLUSIONS: Specialised multidisciplinary tinnitus based on cognitive behav-
ioural therapy is cost-effective as compared to usual care. Although uncertainty
surrounding the incremental costs and effects is considerable, sensitivity analysis
indicated that cost-effectiveness results were robust.
PSS14
COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF
MODERATE TO SEVERE PSORIASIS IN GERMANY
Betts K1, Yan Y2, Sundaram M3, Hengst N4, Wolff M4, Bensimon AG1
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3Abbott
Laboratories, Abbott Park, IL, USA, 4Abbott GmbH & Co. KG, Ludwigshafen, Germany
OBJECTIVES: Etanercept, infliximab, ustekinumab, and adalimumab have been
granted marketing authorization for the treatment of moderate-to-severe psoriasis
in Germany. The objective of this study is to evaluate cost-effectiveness of biologic
treatments from the German Social Health Insurance (SHI) perspective.METHODS:
A simple decision model was constructed to assess the cost-effectiveness of bio-
logics compared to supportive care for the treatment of moderate-to-severe psori-
asis over a one-year time horizon. Clinical efficacy was based on the relative prob-
abilities of achieving PASI75, and PASI 90 response obtained via a network meta-
analysis. Weight-based dosing was assumed for infliximab and ustekinumab.
Costs were assessed in terms of 2012 euros, and included drug acquisition, admin-
istration, laboratory tests, clinic visits, and hospitalization costs. Cost-effective-
ness from payer perspective was assessed as the cost-per-PASI75 response and
cost-per-PASI90 response compared with supportive care (no systemic therapy)
over a one-year time horizon. One-way sensitivity analyses, where key parameters
were changed to alternative plausible values, explored uncertainty in the results.
RESULTS: In the base case, adalimumab was found to be the most cost-effective
compared to supportive care (€25,378 per PASI75 responder and €46,870 per PASI90
responder), followed by infliximab (€30,719 per PASI75 responder and €47,300 per
PASI90 responder), ustekinumab (€31,953 per PASI75 responder, and €57,852 per
PASI90 responder), etanercept 50mg BIW (€43,049 per PASI75 responder and
€101,306 per PASI90 responder), and etanercept 25 mg BIW (€43,156 per PASI75
responder and €111,369 per PASI90 responder). The incremental cost per PASI 75
responder gained and the incremental cost per PASI 90 for infliximab compared to
adalimumab were €51,812 and €48,112, and €87,942 and €106,911 respectively for
ustekinumab. Adalimumab remained the most cost-effective over the vast major-
ity of the one-way sensitivity analyses. CONCLUSIONS: This study found that ada-
limumab is the most cost-effective biologic treatment for moderate to severe pso-
riasis from the German SHI perspective.
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OBJECTIVES: Atopic dermatitis (AD) affects more than 15% of the population car-
rying a heavy burden in developed countries and leading to significant losses in
patients’ quality of life, especially in children. Although no cure has yet been found
for AD, novel drugs such as tacrolimus have been released in recent years. There-
fore this study aimed to perform a cost-effectiveness analysis comparing tacroli-
mus 0.1% ointment with ciclosporin 100mg for the treatment of moderate to severe
AD from the Portuguese societal perspective. METHODS: An individual simulation
event process was designed to mimic the natural course and treatment of the
disease, including relapse and maintenance phases. Time to remission and time to
relapse were simulated according to data from a 6-week randomised trial between
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